Objectives.

Analyze the benefit-risk ratio of FT (Hebertrans®) in medical practice.

Method:

The Bayesian approach was used to compare the likelihood of benefit (satisfactory evolution of patients) with risk (presence of adverse reactions during or after treatment). The information was obtained from publications investigating adverse reactions and the clinical evolution of patients treated with Hebertrans®.

Results:

A higher percentage of adverse reactions was observed with patients who evolved in an unsatisfactory way (24.5%), than among those who progressed correctly (12.2%). The difference between benefit and risk favored the first (Bayes Factor = 2.3).

Conclusions:

The benefit-risk balance for the use of the transfer factor (Hebertrans®) was in favor of the benefit, despite the fact that the clinical evolution of patients is not satisfactory, this drug causes few adverse reactions; the most frequent are related to the administration site and are mild. However, controlled epidemiological studies are necessary to verify these results.

        · abstract in Spanish | French | Portuguese     · text in Spanish     · Spanish ( pdf )